secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001437749-23-013762
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports Q1 2023 cash of $37.3M, R&D expense up to $5.7M; Annamycin trial advances
--------------------------------------------------------------------------------

- Cash and equivalents of $37.3M as of March 31, 2023, expected to fund operations into Q3 2024.
- R&D expense increased to $5.7M from $4.6M YoY, primarily due to WPD sublicense termination.
- G&A expense increased to $2.6M from $2.4M YoY, driven by higher regulatory, legal, and consulting fees.
- Phase 1b/2 trial of Annamycin in AML (MB-106) completed first cohort; positive preclinical data presented at AACR 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923013762/0001437749-23-013762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923013762/mbrx20230508c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-013762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer